An excerpt from a recent article including Dr. Shore in the Urology Times (click here to read full article)
Dr. Neal Shore, MD, FACS
“I’m excited for potential FDA approval of 2 intravascular therapies for high-risk, non–muscle invasive bladder cancer [that is] unresponsive to BCG. These include nadofaragene firadenovec, an investigational gene therapy by FerGene, and oportuzumab monatox, a recombinant fusion protein by Sesen Bio. These 2 therapies will join pembrolizumab [Keytruda], the first drug for patients unresponsive to BCG that was just approved this year that could allow these patients to avoid a cystectomy.
In prostate cancer, we should have the announcement of the phase 3 VISION trial results of the novel therapeutic drug Lu-PSMA-617, a prostate-specific membrane antigen–targeting agent used to deliver radionuclide therapy for the treatment of advanced
prostate cancer patients with [metastatic castration-resistant prostate cancer]. This would add another new therapeutic with a distinct mechanism of action.
But I’m most excited about the FDA approval of the first and only oral [gonadotropin-releasing hormone] antagonist, relugolix (Orgovyx, Myovant Sciences), for androgen deprivation for patients with advanced prostate cancer. It offers enhanced cardiovascular safety and an enhanced mechanism of action as an antagonist. It has faster, more profound testosterone suppression and a shorter course of therapy.
Fortunately, our research program has not been deterred by the pandemic, and we’ve not experienced any setbacks in monitoring our patients or in accruing new subjects.
Our clinic, both outpatient and inpatient schedules, has been very busy. But personally, I haven’t been traveling anywhere near the degree I was, so it has allowed me to be more productive regarding my educational endeavors and